Q-omics provides the consensus-scored MDN1 profile across patient tissues and cancer cell-line models. MDN1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MDN1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, MDN1 protein abundance shows 33,455 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, KICH, and GBM as cancer lineages where MDN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MDN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MDN1 survival associations across molecular data types. MDN1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MDN1 RNA expression–survival associations across cancer types. High MDN1 expression shows unfavorable associations in MESO, BLCA and ACC, but favorable associations in SCLC, KIRC and UCS. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for MDN1 RNA expression.
This table summarizes MDN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MDN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MDN1 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in STAD, LUSC and COAD. The KICH box plot shows higher MDN1 RNA expression in normal versus tumor tissue (log2 FC = −1.314, t-test p < 0.001).
This table shows molecular features associated with MDN1 in patient tissues and cancer cell lines. In patient samples, MDN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MDN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
